Bifogade filer
PDF
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
AcouSort AB (publ) ("AcouSort", the "Company") today announces that the Company and its partner within critical care diagnostics have updated their collaboration agreement. The updated agreement follows the FDA approval in the fall of 2023 for the partnering company's next generation point-of-care diagnostic system containing AcouSort's acoustofluidics technology. Minimum revenues from the partnership in 2024 are expected to reach approximately SEK 3.5M.
AcouSort and its partner within critical care diagnostics have updated their collaboration agreement, and the commercial phase of the collaboration will start at the beginning of 2024. Both minimum and per product royalties have been index adjusted going forward and AcouSort's minimum revenues from the partnership in 2024 is expected to be around SEK 3.5 million.
"The collaboration with this partnering company is the first full-blown success for our research-to-OEM strategy and serves as proof-of-concept of our business model. The commercialization of our partnering company's new system with integrated acoustofluidics technology is one of the most significant milestones in the history of AcouSort and we could not be happier. The FDA approval is a validation of our technology that greatly strengthens our market position across all discussions with potential diagnostic and life science partners," says Torsten Freltoft, AcouSort's CEO.
This information is information that AcouSort AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted, through the agency of the contact person below, for publication on December 11, 2023, at 10.00 pm.